Veteran tech analyst Paul Meeks said that CoreWeave’s backstop from Nvidia could absorb “any extra capacity for seven years” given their GPU partnership.
Wall Street’s top picks for 2026: JPMorgan says a rare biopharma stock could more than triple
JPMorgan sees shares of Ultragenyx Pharmaceutical soaring more than 200% from current prices.
Wall Street traders see good chance for a ‘FOMO-driven chase’ that lifts stocks into year-end
Under-invested traders continue to get swayed into participating in the market by the fear of missing out, according to Citadel.
Netflix shares are falling on Warner Bros. tie-up. What the deal means for the stock
Rich Greenfield, LightShed Partners co-founder, believes the economics of the transaction are likely to weigh on Netflix before they help in the long term.
Wall Street loves Meta’s reported metaverse cuts. Most analysts see 20%-plus gain for stock
Analysts believe that Meta’s reported metaverse cuts underline its strong cost discipline and continued focus on efficiency and growth.
Morgan Stanley upgrades rare earth stock, says the U.S. has chosen it as solution to China’s dominance
Morgan Stanley believes that shares of MP Materials could rise another 15% from here.
Some AI stocks that trade at a reasonable price, according to Citigroup
Citigroup’s “AI at a Reasonable Price” basket offers an avenue for individuals into AI using a diversified set of stocks, such as Meta, Eaton and Adobe.
Meta is rebounding on report of job cuts. Why Stephanie Link is adding to her position
Hightower Advisors’ Link said she expects the Facebook parent’s stock to rise further.
An under-the-radar medical device stock with 20% upside, according to the charts
Jay Woods breaks down the charts in Steris.
Where to lock in 4% yields on CDs ahead of likely Fed rate cut
CD rates are down from their highs but still offer solid returns.